HomeAI · summaries
Storia in 2 fonti
FDA Scientists Raise Questions About Duchenne Drug
Agency says deramiocel did not meet phase III trial endpoints, contrary to reported data
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug
Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.
- ·
medpagetoday.com
FDA Scientists Raise Questions About Duchenne Drug
Agency says deramiocel did not meet phase III trial endpoints, contrary to reported data